Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

Effect of Gum Arabic on Kidney Function in Dialysis Patients

Official title: The Effect of Gum Arabic (GA) on Adult Dialysis Patients in Abu Dhabi: A Prospective Randomized-controlled Trial (The GADAD Study)

Run by Abu Dhabi Health Services Company · NCT06836206 · Data updated 2026-11-12

This study is testing if adding Gum Arabic to the treatment of dialysis patients with kidney failure can improve their kidney function and overall health.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorAbu Dhabi Health Services Company
Government
Locations1 site (Abu Dhabi)
StatusRecruiting
StartedFebruary 3, 2025
Main results expectedNovember 30, 2025
Study endsApril 30, 2026
Registry record updatedFebruary 20, 2025
Trial IDNCT06836206 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with diagnosed ESRD who are currently on regular dialysis and have some residual renal function.

Probably not a fit

Patients who do not produce any urine or have advanced ESRD with no residual renal function may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of Gum Arabic (GA) on residual renal function in adult patients with end-stage renal disease (ESRD) who are undergoing dialysis. Participants will receive GA supplementation alongside their regular treatment to assess its effects on various renal and metabolic parameters. The study aims to gather evidence on the potential benefits of GA, which has been traditionally used for its health properties, particularly in renal health. The trial will involve a comprehensive evaluation over a maximum period of 266 days.

Why it matters

Potential benefit: If successful, this study could improve kidney function and overall health outcomes for dialysis patients.

How similar studies have gone: Previous studies have shown promising results regarding the effects of Gum Arabic on renal health, suggesting potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

To be eligible to participate in this trial, an individual must meet all the following criteria:

1. Men and women ≥18 years of age with diagnosed ESRD and prescribed regular dialysis at least once a week, weekly at least for past two weeks.
2. For past two weeks including women of childbearing potential who are currently adopting any method of contraception or have completed the family and undergone sterilization procedures and women of non-childbearing potential.
3. Patients with residual renal function - Patients who produce a minimum of 200 ml of urine during a full day of collection (A full day collection: the patient discards the first urine sample on the day of collection then collects all urine for the entire day and night and collects the first urine sample of the next day) r on a non-dialysis long break day.
4. Able and willing to complete the whole period of the study (maximum of 266 days from enrolment).
5. With the ability to understand the study procedures, the informed consent \& voluntarily sign an informed consent form and be able to comply with the requirements of the protocol.

Exclusion Criteria:

1. Women of childbearing potential not adopting any methods of contraception, have not undergone sterilization.
2. Women Pregnant or lactating
3. Patients who plan to conceive (or for their partners to conceive) within 12 months of randomization.
4. Patient presenting with serum K+levels ≥ 6mmol/L based on the last two reports as per medical records.
5. Patients who produce less than 200 ml of urine during 24 hours urine collection at baseline assessment.
6. Peritoneal dialysis.
7. Kidney transplant or booked for a live transplant within 259 days of randomization.
8. Patients gaining \>4 kg between dialysis sessions in the past 2 weeks.
9. People with known allergies to quillaja bark or similar tree bark.
10. Patients are already participating in another clinical trial (excluding COVID-19 vaccine or COVID-19 drug trials).
11. Patients on immunosuppression for kidney transplant.

Additional exclusion criteria for follow-up visits.

1. Patient informs of pregnancy.
2. Severe adverse reaction to the interventional product.

Where it's running

  • SEHA Kidney Care (SKC)
    Abu Dhabi, United Arab Emirates
    Recruiting

Study contacts

  • Principal investigator: Stephen G Holt, MD — Abu Dhabi Health Services Co. -SEHA
  • Study coordinator: Stephen G Holt, MD
  • Email: sholt@seha.ae
  • Phone: +971 2 711 7444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.